Toronto, Ontario--(Newsfile Corp. - November 4, 2024) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare technology company focused on AI and data science for preventative care, is pleased to announce the Company will release its Fiscal Third Quarter 2024 financial results for the period ended September 30, 2024, on Tuesday, November 12, 2024. The Company will hold a conference call and simultaneous webcast to discuss its results on the same day at 1:00 pm EST (10:00 am PST). The call will be hosted by Dr. Alexander Dobranowski, Chief Executive Officer, and Anthony Lam, Chief Financial Officer.
HEALWELL AI Third Quarter 2025 Results Conference Call
Date: Tuesday, November 12, 2024
Time: 1:00 PM ET / 10:00 AM PT
Webcast link: https://www.gowebcasting.com/13843
Toll-Free North America: 1-844-763-8274
International Toll: 1-647-484-8814
When connecting to the conference call via phone, please dial in 10 minutes prior to the start of the call and ask to join the "HEALWELL AI Inc. Conference Call."
Dr. Alexander Dobranowski
Chief Executive Officer
HEALWELL AI
About HEALWELL
HEALWELL is a healthcare technology company focused on AI and data science for preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary technology, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is executing a strategy centered around developing and acquiring technology and clinical sciences capabilities that complement the Company's road map. HEALWELL is publicly traded on the Toronto Stock Exchange (the "TSX") under the symbol "AIDX" and on the OTC Exchange under the symbol "HWAIF". To learn more about HEALWELL, please visit https://healwell.ai/.
For more information:
Pardeep Sangha
Investor Relations, HEALWELL AI Inc.
Phone: 604-572-6392
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | C$2.10 |
| Daily Change: | -0.09 -4.11 |
| Daily Volume: | 1,938,211 |
| Market Cap: | C$348.350M |
December 03, 2024 November 12, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
